Candel Therapeutics (NASDAQ:CADL – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.
Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group lowered their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research report on Thursday, October 22nd. They set a “buy” rating and a $25.00 price objective on the stock. HC Wainwright reduced their target price on shares of Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Wall Street Zen downgraded shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Finally, Stifel Nicolaus decreased their target price on shares of Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 13th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.29.
Read Our Latest Report on CADL
Candel Therapeutics Price Performance
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Analysts forecast that Candel Therapeutics will post -1.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in CADL. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Candel Therapeutics in the 3rd quarter worth approximately $41,000. Legal & General Group Plc acquired a new position in Candel Therapeutics during the second quarter valued at approximately $63,000. Cetera Investment Advisers acquired a new position in Candel Therapeutics during the third quarter valued at approximately $124,000. Renaissance Technologies LLC bought a new position in shares of Candel Therapeutics in the first quarter valued at approximately $63,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock valued at $152,000 after purchasing an additional 2,301 shares during the period. Institutional investors and hedge funds own 13.93% of the company’s stock.
Key Stories Impacting Candel Therapeutics
Investors following CADL have been watching these stories:
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
- Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Further Reading
- Five stocks we like better than Candel Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
